TMCnet News

United States Procedure Numbers for Orthopedic Biomaterials 2017 - Research and Markets

[March 08, 2017]

United States Procedure Numbers for Orthopedic Biomaterials 2017 - Research and Markets

Research and Markets has announced the addition of the "US Procedure Numbers for Orthopedic Biomaterials 2017 - MedPro" report to their offering.

Orthopedic biomaterials are associated with high research and development (R&D) costs, which have subsequently led to premium pricing to recoup these initial costs. This is the case for competitors in the cellular allograft, cell therapy and growth factor segments of the U.S. orthopedic biomaterials market. In particular, orthopedic growth factors have had relatively high average selling prices (ASP) since their introduction to the market due to the high costs of recombinant growth factor technologies.

The high R&D costs associated with the growth factor segment provide entry barriers against potential competitors. Currently there are only two growt factor BMP-2 products in the United States. Since they're both used in different indications, there is a lack of direct competition, allowing companies such as Medtronic to charge a premium for the Spine indication and recover the large initial costs associated with R&D.

The commoditized nature in some parts of the market, such as the allograft and DBM segments, which is due to the lack of product differentiation, has limited growth. The market is being driven by more competitors venturing outside their traditional space to tap into the high growth segments where they can charge a premium. These segments may include the cell therapy and cellular allograft segments, both of which have relatively high ASP.

Key Topics Covered:

1. Research Methodology

2. Disease Overview

3. Procedure Numbers

Companies Mentioned

- Medtronic

- Genzyme

- DePuy Synthes

- Anika Therapeutics

- Ferring Pharmaceuticals

- Stryker

- NuVasive